Alongside new steps in its therapeutic pipeline—and a new push into laboratory robotics—Insilico Medicine has raised $110 ...

GSK’s ViiV Healthcare has shared clinical data on three potential long-acting HIV treatments, providing a look at how its ...

Johnson & Johnson MedTech has secured an FDA clearance for new artificial intelligence-powered guidance systems to support ...

China’s Harbour BioMed has launched a new biotech to develop bispecific antibodies focused on the holy grail of next-gen ...

Tech firm Clario is boosting its electronic clinical outcome assessment (eCOA) offerings by acquiring the ...

Japan's Ono Pharmaceutical is handing over $280 million upfront to acquire Ionis Pharmaceuticals’ phase 2-stage antisense ...

Emergent BioSolutions is investing in Swiss biotech Rocketvax, inking a deal designed to fuel the preclinical company’s R&D. | Emergent BioSolutions is investing in Swiss biotech Rocketvax, inking a ...

The drug in question, called vepdegestrant, is an oral PROteolysis TArgeting Chimera (PROTAC) ER degrader. The phase 3 study ...

Two years after first announcing the partnership, Boehringer Ingelheim and software firm Veeva Systems have launched ...

Roche is paying $1.65 billion in confirmed upfront fees to add to its burgeoning obesity pipelin | Roche is paying $1.65 ...

Coherus BioSciences will see its workforce shrink once again as the result of the recently agreed sale of its Neulasta ...

Lila Sciences is looking to use $200 million in seed funding to develop advanced AI that can power fully autonomous research ...